Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Risk factor for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy

Article Abstract:

The incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy are evaluated. The results suggest that coadminstration of ribavirin and didanosine should be avoided, and if unavoidable, the patients should be monitored closely for mitochondrial toxicity.

Author: Bani-Sadr, Firouze; Carrat, Fabrice; Pol, Stanislas, Hor, Ravy; Rosenthal, Eric; Goujard, Cecile; Morand, Patrice, Lunel-Fabiani, Francoise; Salmon-Ceron, Dominique, Piroth, Lionel; Pialoux, Gilles, Bentata, Michele; Cacoub, Patrice; Perronne, Christian
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
United States, Dosage and administration, Didanosine, Ribavirin, Hepatitis C virus

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation

Article Abstract:

Doctors should be cautious about discontinuing anti-tuberculosis drugs in HIV patients who are taking AIDS drugs even if their immune system seems to recover. In a study of 13 HIV patients, cellular immunity against tuberculosis did not increase even though they were taking AIDS drugs.

Author: Hung, Chien-Ching, Chen, Mao-Yuan, Hsieh, Szu-Min, Chang, Shan-Chwen, Pan, Sung-Ching, Wang, Jann-Tay, Tsai, Hsing-chun
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
Research, Physiological aspects, Tuberculosis, Immunity, Immunity (Physiology)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study

Article Abstract:

The use of highly active antiretroviral therapy (HAART) in Taiwan has cut the mortality rate from AIDS by more than 50%. HAART has been provided free of charge to many AIDS patients since 1997.

Author: Hung, Chien-Ching, Chen, Mao-Yuan, Hsieh, Szu-Min, Sheng, Wang-Hwei, Chang, Shan-Chwen
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
Taiwan, Health aspects, Statistical Data Included, Patient outcomes, Mortality, AIDS (Disease)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: HIV infection, Drug therapy, HIV infections
Similar abstracts:
  • Abstracts: Incidence of immune reconstitution syndrome in HIV/Tuberculosis-Coinfected patients after intiation of generic antiretroviral therapy in India
  • Abstracts: The detection of struma ovarii in two patients by radioimmunoscintigraphy. Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody
  • Abstracts: Methadone dosing strategies in HIV-infected injection drug uses enrolled in a directly observed therapy program
  • Abstracts: The continuing effectiveness of active management of first labor, despite a doubling in overall nulliparous cesarean delivery
  • Abstracts: A detailed comparison of physician services for the elderly in the United States and Canada. Gender Disparities in the Receipt of Home Care for Elderly People With Disability in the United States
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.